Amylyx Pharmaceuticals, Inc.
AMLX
Clasificación en acciones
#4500
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Precio por acción
$27.25
Capitalización bursátil
$3.42B
Cambio (1 día)
3.45%
Cambio (1 año)
82.27%
País
US
Comercio Amylyx Pharmaceuticals, Inc. (AMLX)
Categoría
Healthcare
Historial de dividendos de Amylyx Pharmaceuticals, Inc. (AMLX)
Amylyx Pharmaceuticals, Inc. (símbolo bursátil: AMLX) realizó un total de 3 pagos de dividendos.
La suma de todos los dividendos (ajustados por splits de acciones) es: $1.02
Rentabilidad por dividendo (TTM): 0
La suma de todos los dividendos (ajustados por splits de acciones) es: $1.02
Rentabilidad por dividendo (TTM): 0
Pagos de dividendos de Amylyx Pharmaceuticals, Inc. (AMLX) desde 2017 hasta 2026
Pagos anuales de dividendos
| Año | Dividendo (ajustado por splits de acciones) | Cambiar |
|---|---|---|
| 2026 (TTM) | $0.42 | 0.00% |
| 2018 | $0.42 | -30.00% |
| 2017 | $0.6 | 0.00% |
Lista de todos los pagos de dividendos
| Año | Dividendo | Cambiar |
|---|---|---|
| 2026 (TTM) | $0.42 | 0.00% |
| 2018 | $0.42 | -30.00% |
| 2017 | $0.6 | 0.00% |
Pagos de dividendos de empresas similares o competidoras
| Empresa | Número de pagos de dividendos | País |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 64.00% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
